Use of proteomic analysis to monitor responses to biological therapies

Bibliography

• LI J, ZHANG Z, ROSENZWEIG J,WANG YY, CHAN DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. (2002) 8:1296–1304.
   Google Scholar
• •Identified three potential biomarkers for breast cancer via SELDI mass spectrometry.
   Google Scholar
• STETSON SJ, PEREZ-VERDIA A, MAZUR W et al: Cardiac hypertrophy after transplantation is associated with persistent expression of tumor necrosis factor-alpha. Circulation (2001) 6:676–681.
   Google Scholar
• DOMENECH N, CRESPO-LEIRO MG,MOSCOSO I et al.: Neither acute rejection nor immunosuppressant drug therapy (cyclosporine or tacrolimus) correlates with expression of either CD40 or CD154 on peripheral blood cells among human cardiac transplant patients. Transplant. Proc. (2003) 5:1994–1995.
   Google Scholar
• CELIS JE, GROMOV P: Proteomics in translational cancer research: toward an integrated approach. Cancer Cell (2003) 1:9–15.
   Google Scholar
• CHEN G, GHARIB TG, HUANG CC et al.: Proteomic analysis of lung adenocarcinoma: identification of a highlyexpressed set of proteins in tumors. Clin. Cancer Res. (2002) 7:2298–2305.
   Google Scholar
• DELEHANTY JB, LIGLER FS: A microarray immunoassay for simultaneous detection of proteins and bacteria. Anal. Chem. (2002) 21:5681–5687.
   Google Scholar
• PANDEY A, MANN M: Proteomics to study genes and genomes. Nature (2000) 6788:837–846.
   Google Scholar
• ISSAQ HJ, VEENSTRA TD, CONRADS TP, FELSCHOW D: The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun. (2002) 3:587–592.
   Google Scholar
• WULFKUHLE JD, SGROI DC, KRUTZSCH H et al.: Proteomics of human breast ductal carcinoma in situ. Cancer Res. (2002) 22:6740–6749.
   Google Scholar
• VENTER JC, ADAMS MD, MYERS EW et al.: The sequence of the human genome. Science (2001) 5507:1304–1351.
   Google Scholar
• •Description of complexity of the human genome.
   Google Scholar
• EMMERT-BUCK MR,STRAUSBERG RL, KRIZMAN DB et al.: Molecular profiling of clinical tissue specimens: feasibility and applications. Am. Pathol (2000) 4:1109–1115.
   Google Scholar
• KNEZEVIC V, LEETHANAKUL C, BICHSEL VE et al.: Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomic( 2001) 10:1271–1278.
   Google Scholar
• ••Differential protein expression in stromalcells in the vicinity of oral squarnous cell cancer correlated with tumour progression.
   Google Scholar
• LIOTTA L, PETRICOIN E: Molecular profiling of human cancer. Nat. Rev. Genet. (2000) 1:48–56.
   PubMed Web of Science ®Google Scholar
• ••Combination of genomic and proteomicprofiling for effective monitoring of biological response.
   Google Scholar
• PAWELETZ CP, TROCK B,PENNANEN M et al.: Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers (2001) 4:301–307.
   Google Scholar
• PAWELETZ CP, CHARBONEAU L, BICHSEL VE et al.: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 16:1981–1989.
   Google Scholar
• ••Demonstrated utility of proteinmicroarrays in prostate cancer profiling.
   Google Scholar
• PETRICOIN EF 3RD, ORNSTEIN DK, PAWELETZ CP et al.: Serum proteomic patterns for detection of prostate cancer. Natl. Cancer Inst. (2002) 20:1576–1578.
   Google Scholar
• ••Predicted prostate cancer by serum proteinprofiling using SELDI mass spectrometry for patients with PSA levels 4 ng/ml.
   Google Scholar
• PETRICOIN EF, ARDEKANI AM, HITT BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 9306:572–577.
   Google Scholar
• ••Serum proteomic patterns generated bySELDI mass spectrometry correctly clustered sera from patients with ovarian cancer with 100% sensitivity and 95% specificity as compared with normal sera.
   Google Scholar
• CLARKE W, SILVERMAN BC, ZHANG Z et al.: Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Stag. (2003) 5:660-664;discussion 664–665.
   Google Scholar
• ••Identified five urine biomarkers fordistinguishing renal allograft rejection with 83% sensitivity and 100% specificity
   Google Scholar
• URBANOWSKA T, MANGIALAIO S, HARTMANN C, LEGAY F: Development of protein microarray technology to monitor biomarkers of rheumatoid arthritis disease. Cell Biol. Toxicol (2003) 3:189–202.
   Google Scholar
• CARRETTE O, DEMALTE I, SCHERL A et al.: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomic s (2003) 8:1486–1494.
   Google Scholar
• SHIPP MA, ROSS KN, TAMAYO P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 1:68–74.
   Google Scholar
• SINGH D, FEBBO PG, ROSS K et al: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 2:203–209.
   Google Scholar
• SCHWARTZ DR, KARDIA SL, SHEDDEN KA et al.: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. (2002) 16:4722–4729.
   Google Scholar
• SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 19:10869–10874.
   Google Scholar
• STAUDT LM: Gene expression profiling of lymphoid malignancies. Anna. Rev Med. (2002) 53:303–318.
   PubMed Web of Science ®Google Scholar
• PEGORARO L, PALUMBO A, ERIKSON J et aL: A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc. Natl. Acad. Sci. USA (1984) 22:7166–7170.
   Google Scholar
• REED JC, HALDAR S, CUDDY MP, CROCE C, MAKOVER D: Deregulated BCL2 expression enhances growth of a human B cell line. Oncogene (1989) 9:1123–1127.
   Google Scholar
• KINGSM ORE SF, PATEL DD: Multiplexed protein profiling on antibody-based microarrays by rolling circle amplification. Curt: Opin. Biotechnol (2003) 1:74–81.
   Google Scholar
• LIOTTA LA, KOHN EC,PETRICOIN EF: Clinical proteomics: personalized molecular medicine. JAMA(2001) 18:2211–2214.
   Google Scholar
• ••Discussion of protein-targeted therapyand proteomic profiling forindividualised therapy.
   Google Scholar
• LIOTTA LA, ESPINA V, MEHTA Al et al.: Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell (2003) 4:317–325.
   Google Scholar
• ••In-depth discussion of technicalaspects of protein microarrays for clinical applications.
   Google Scholar
• MANN M, HENDRICKSON RC, PANDEY A: Analysis of proteins and proteomes by mass spectrometry. Anna. Rev Biochem. (2001) 70:437–473.
   PubMed Web of Science ®Google Scholar
• PETRICOIN EF, ZOON KC, KOHN EC, BARRETT JC, LIOTTA LA: Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev Drug Discov. (2002) 9:683–695.
   Google Scholar
• SREEKUMAR A, NYATI MK,VARAMBALLY S et al.: Profiling of cancer cells using protein microarrays: discovery of novel radiation-regulated proteins. Cancer Res. (2001) 20:7585–7593.
   Google Scholar
• TEMPLIN ME STOLL D, SCHRENK M et al.: Protein microarray technology. Trends Biotech. (2002) 4:160–166.
   Google Scholar
• WULFKUHLE JD, PAWELETZ CP, STEEG PS, PETRICOIN EF 3RD, LIOTTA L: Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv. Exp. Med. Biol. (2003) 532:59–68.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA K, SHYR Y, XU BJ et al.:Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 9382:433–439.
   Google Scholar
• ZHU H, SNYDER M: Protein chip technology. Curr. Opin. Chem. Biol. (2003) 1:55–63.
   Google Scholar
• CONRADS TP, FUSARO VA, ROSS S et al.: Multiple high-resolution serum proteomic features for ovarian detection. Endocr: Relat. Cancer (Submitted).
   Google Scholar
• CHUNG CH, BERNARD PS,PEROU CM: Molecular portraits and the family tree of cancer. Nat. Genet. (2002) 32(Suppl.):533–540.
   Google Scholar
• •Discussion of histological clustering, genetic microarrays and hierarchical clustering as related to cancer profiling.
   Google Scholar
• CHUNG GG, KIELHORN EP,RIMM DL: Subjective differences in outcome are seen as a function of the immunohistochemical method used on a colorectal cancer tissue microarray. Clin. Colorectal Cancer (2002) 1(4):237–242.
   PubMedGoogle Scholar
• NAM JM, THAXTON CS, MIRKIN CA: Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science (2003) 5641:1884–1886.
   Google Scholar
• LIOTTA LA, CLAIR T: Cancer. Checkpoint for invasion. Nature (2000) 6784:287–288.
   Google Scholar
• LIOTTA LA, KOHN EC: The microenvironment of the tumour-host interface. Nature (2001) 6835:375–379.
   Web of Science ®Google Scholar
• ••Use of stromal therapy as a new strategyfor cancer treatment.
   Google Scholar
• LIOTTA LA: An attractive force in metastasis. Nature (2001) 6824:24–25.
   Google Scholar
• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 1:57–70.
   Google Scholar
• HUNTER T: Signaling - 2000 and beyond. Cell (2000) 1:113–127.
   Google Scholar
• OLTVAI ZN, BARABASI AL: Systems biology. Life's complexity pyramid. Science (2002) 5594:763–764.
   Google Scholar
• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 6835:355–365.
   Google Scholar
• BOWDEN ET, BARTH M, THOMAS D, GLAZER RI, MUELLER SC: An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene (1999) 31:4440–4449.
   Google Scholar
• •Demonstrated correlation between invasion potential and matrix degradation of invasive breast cancer cells.
   Google Scholar
• JEONG H, TOMBOR B, ALBERT R, OLTVAI ZN, BARABASI AL: The large-scale organization of metabolic networks. Nature (2000) 6804:651–654.
   Google Scholar
• PETRICOIN EF, LIOTTA LA: Clinical applications of proteomics. Num (2003) 7(Suppl.):2476S–2484S.
   Google Scholar
• AHRAM M, FLAIG MJ, GILLESPIE JW et al.: Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics (2003) 4:413–421.
   Google Scholar
• CHARBONEAU L: Utility of reverse phaseprotein arrays: applications to signaling pathways and human body arrays.Brief Funct. Cenomics Proteomics (2002) 3:305–315.
   Google Scholar
• SIMONE NL, REMALEY AT, CHARBONEAU L et al.: Sensitive immunoassay of tissue cell proteinsprocured by laser capture microdissection. Am. J. Pathol (2000) 2:445–452.
   Google Scholar
• DARE TO, DAVIES HA, TURTON JA et al.: Application of surface-enhanced laser desorption/ionization technology to the detection and identification of urinary parvalbumin-alpha: a biomarker of compound-induced skeletal muscle toxicity in the rat. Electrophoresis (2002) 18:3241–3251.
   Google Scholar
• FETSCH PA, SIMONE NL, BRYANT-GREENWOOD PK et al.: Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am. J. Clin. Pathol (2002) 6:870–876.
   Google Scholar
• ISSAQ HJ, CONRADS TP, PRIETO DA,TIRUMALAI R, VEENSTRA TD: SELDI-TOF MS for diagnostic proteomics. Anal. Chem. (2003) 7:148A–155A.
   Google Scholar
• HUTCHENS TW, YIP T-T: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Specmom. (1993) 7:576–580.
   Web of Science ®Google Scholar
• MERCHANT M, WEINBERGER SR: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis (2000) 6:1164–1177.
   Google Scholar
• ISSAQ HJ, CONRADS TP, JANINI GM,VEENSTRA TD: Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis (2002) 17:3048–3061.
   Google Scholar
• CONRADS TP, ZHOU M,PETRICOIN EF, LIOTTA LA, VEENSTRA TD: Cancer diagnosis using proteomic patterns. Expert Rev Ma Diagn. (2003) 4:411–420.
   Google Scholar
• •Technical discussion of mass spectrometry profiling for ovarian and prostate cancer.
   Google Scholar
• BATORFI J, YE B, MOK SC et al: Proteinprofiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Cynecol Oncol (2003) 3:424–428.
   Google Scholar
• •Identified three proteins differentially expressed in placental complete mole cells as compared with normal placenta.
   Google Scholar
• HAMPEL H, GOERNITZ A, BUERGER K: Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull. (2003) 3:243–253.
   Google Scholar
• YASUI Y, PEPE M, THOMPSON ML et al.: A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 3:449–463.
   Google Scholar
• PETRICOIN EE, PAWELETZ CP, LIOTTA LA: Clinical applications of proteomics: proteomic pattern diagnostics. J. Mammary Gland Biol. Neoplasia (2002) 4:433–440.
   Google Scholar
• LEWCZUK P, ESSELMANN H, MEYER M et al: The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun. Mass Specmom. (2003) 12:1291–1296.
   Google Scholar
• BONK T, HUMENY A, SUTTER C et al.: Molecular diagnosis of familial adenomatous polyposis (FAP): genotyping of adenomatous polyposis coli (APC) alleles by MALDI-TOF mass spectrometry. Clin. Biochem. (2002) 2:87–92.
   Google Scholar
• BONK T, HUMENY A, GEBERT Jet al.: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry-based detection of microsatellite instabilities in coding DNA sequences: a novel approach to identify DNA-mismatch repair-deficient cancer cells. Clin. Chem. (2003) 4:552–561.
   Google Scholar
• CONRADS TP, ZHOU M,PETRICOIN EF 3RD, LIOTTA L, VEENSTRA TD: Cancer diagnosis using proteomic patterns. Expert Rev Ma Diagn. (2003) 4:411–420.
   Google Scholar
• JESSANI N, LIU Y, HUMPHREY M, CRAVATT BF: Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA (2002) 16:10335–10340.
   Google Scholar
• IDEKER T, THORSSON V, RANISH JA et al.: Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science (2001) 5518:929–934.
   Google Scholar
• PHIZICKY E, BASTIAENS PI, ZHU H,SNYDER M, FIELDS S: Protein analysis on a proteomic scale. Nature (2003) 6928:208–215.
   Google Scholar
• TYERS M, MANN M: From genomics to proteomics. Nature (2003) 6928:193–197.
   Google Scholar
• ••Discussion of proteomic applicationsand of technological innovations and projects that may fulfil the profiling potential of proteomics.
   Google Scholar
• WILSON DS, NOCK S: Recent developments in protein microarray technology. Angew Chem. mt. Ed. Engl. (2003) 5:494–500.
   Google Scholar
• LAL SP, CHRISTOPHERSON RI, DOS REMEDIOS CG: Antibody arrays: an embryonic but rapidly growing technology. Drug Discov. Today (2002) 18(Suppl.): S143–S149.
   Google Scholar
• MACBEATH G, SCHREIBER SL: Printing proteins as microarrays for high-throughput function determination. Science (2000) 5485:1760–1763.
   Google Scholar
• PETACH H, GOLD L: Dimensionality is the issue: use of photoaptamers in protein microarrays. Curt Opin. Biotechnol (2002) 13(4):309–314.
   PubMed Web of Science ®Google Scholar
• SCHAEFERLING M, SCHILLER S, PAUL H et al.: Application of self-assembly techniques in the design of biocompatible protein microarray surfaces. Electrophoresis (2002) 18:3097–3105.
   Google Scholar
• WENG S, GU K, HAMMOND PW et al: Generating addressable protein microarrays with PROfusion covalent mRNA-protein fusion technology. Proteomics (2002) 1:48–57.
   Google Scholar
• HUMPHERY-SMITH I,WISCHERHOFF E, HASHIMOTO R:Protein arrays for assessment of target selectivity. Drug Discov. World (2002) 1:17–27.
   Google Scholar
• BACARESE-HAMILTON T, MEZZASOMA L, INGHAM C et al.: Detection of allergen-specific IgE on microarrays by use of signal amplification techniques. Clio. Chem. (2002) 8:1367–1370.
   Google Scholar
• BACARESE-HAMILTON T, GRAY J, CRISANTI A: Protein microarray technology for unraveling the antibody specificity repertoire against microbial proteomes. Curt Opin. Mol. Ther. (2003) 3:278–284.
   Google Scholar
• HUNYADY B, KREMPELS K, HARTA G,MEZEY E: Immunohistochemical signal amplification by catalyzed reporterdeposition and its application in double immunostaining. Histochem. Cytochem.(1996) 12:1353–1362.
   Google Scholar
• KING G, PAYNE S,WALKERF, MURRAY GI: A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. Pathol (1997) 2:237–241.
   Google Scholar
• BOBROW MN, HARRIS TD,SHAUGHNESSY KJ, LITT GJ: Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J. Immunol Methods (1989) 125(1-2):279–285.
   PubMed Web of Science ®Google Scholar
• BOBROW MN, SHAUGHNESSY KJ, LITT GJ: Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. Immunol Methods (1991) 137(1):103–112.
   PubMed Web of Science ®Google Scholar
• EMMERT-BUCK MR, BONNER RF, SMITH PD et al.: Laser capture microdissection. Science (1996) 5289:998–1001.
   Google Scholar
• GILLESPIE JW, BEST CJ, BICHSEL VE et al.: Evaluation of non-formalin tissue fixation for molecular profiling studies. Am. J. Pathol (2002) 2:449–457.
   Google Scholar
• SIMONE NL, PAWELETZ CP,CHARBONEAU L, PETRICOIN EF 3RD, LIOTTA LA: Laser capture microdissection: beyond functional genomics to proteomics. MM. Diagn. (2000) 4:301–307.
   Google Scholar
• LIOTTA LA, KOHN EC: Cancer's deadly signature. Nat. Genet. (2003) 1:10–11.
   Google Scholar
• CARLISLE AJ, PRABHU VV,ELKAHLOUN A et al.: Development of a prostate cDNA microarray and statistical gene expression analysis package. Carcinog. (2000) 1:12–22.
   Google Scholar
• HANASH S: Disease proteomics. Nature (2003) 6928:226–232.
   Google Scholar
• •Discussion of genomic and proteomic technologies for disease profiling.
   Google Scholar
• CHING CD MP, FUSARO V: Proteomic profiling if suspicious lung nodules: differentiating benign nodules from non-small cell lung cancer. In Proceedings of the 94th Annual Meeting of the American Association for Cancer Research.Washington DC (2003).
   Google Scholar
• HOBBS SK, SHI G, HOMER R, HARSH G, ATLAS S, BEDNARSKI M: Magnetic resonance image guided proteomics of human glioblastoma multiforme. In: Proceedings of the 94th Annual Meeting of the American Association for Cancer Research. Washington DC (2003).
   Google Scholar
• MILLER JC, ZHOU H, KWEKEL J et al: Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics (2003) 1:56–63.
   Google Scholar
• ••Identified five serum biomarkersdifferentially expressed in prostate cancer as compared with a control group.
   Google Scholar